0R55.L - BioSenic S.A.
| Previous close | 0.1215 |
| Open | 0.1195 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.1150 - 0.1195 |
| 52-week range | 0.0880 - 0.3455 |
| Volume | |
| Avg. volume | 13,041 |
| Market cap | 11,753 |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7670 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireBioSenic SA : Information on the total number of voting rights and shares
REGULATED INFORMATION Mont-Saint-Guibert, Belgium, June 1st, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in in the areas of innate immunity, inflammation and organ/function repair, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares following the conversion of convertible bonds (CBs). The following information is published in accordance with Article 15 of
- Globe Newswire
BioSenic provides update regarding current license agreement with Phebra
INSIDE INFORMATION Maintenance of the license is now subject to the launch of the OATO Phase III before May 2024 instead of 31 May 2023 Parties also currently negotiating a potential renegotiation of the other licensing terms Mont-Saint-Guibert, Belgium, May 29th 2023, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces the amendment of the license agreement between its
- Globe Newswire
BioSenic and Pluristyx sign term sheet for market availability of ALLOB mesenchymal cells
INSIDE INFORMATION Potential license agreement to produce and commercialize original and transformed ALLOB cells BioSenic to potentially receive royalty rates on net sales up to 25% Mont-Saint-Guibert, Belgium, May 24th 2023, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces the signing of a term sheet with Pluristyx, a leading provider of gene-edited iPSC and cell th
- Globe Newswire
BioSenic provides First Quarter 2023 Business Update
REGULATED INFORMATION ALLOB Phase IIb topline results foreseen in July/August 2023Ongoing discussions for key partnerships with lead clinical assets Mont-Saint-Guibert, Belgium, May 22nd, 2023 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces its business update for the first quarter, ended 31 March 2023. Key highlights Strengthening of Executive Committee and Board o
- Globe Newswire
BioSenic reacquires global IP rights and provides update on JTA-004 development
INSIDE INFORMATION BioSenic plans to further develop its program on an active injectable viscosupplement JTA, combining anti-pain and anti-inflammatory characteristics on a subtype of knee osteoarthritis. Mont-Saint-Guibert, Belgium, May 17th, 2023 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces an update to its future plans for clinical development of BioSenic’s en
- Globe Newswire
BioSenic to host Annual General Meeting on June 14 2023
REGULATED INFORMATION Preliminary documents for the Annual General Meeting have been made available on company’s website Mont-Saint-Guibert, Belgium, May 15th, 2023 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the Annual General Meeting to be held on Wedn
- Globe Newswire
BioSenic identifies key biomarkers for cGvHD and submits patent to EPO
INSIDE INFORMATION International patent to allow the development of an industrial biomarker analysis kit which could generate a turnover of 30 to 40 million euros globally Mont-Saint-Guibert, Belgium, May 4th 2023, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces the submission of a key patent in the use of its ATO platform. The patent, entitled Diagnostic method for
- Globe Newswire
BioSenic announces 2022 full year results
REGULATED INFORMATION ALLOB Phase IIb topline results foreseen in Q2 2023 ATO Phase III to be launched in 2023 Ongoing discussions for key partnerships with lead clinical assets Mont-Saint-Guibert, Belgium, April 27, 2023, 7am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces its business update and full year financial results for the year ending 31 December 2022, prepared in accordance wi
- Globe Newswire
BioSenic receives key European patent from EPO, for further therapeutic development in cancer, infectious and immune diseases
INSIDE INFORMATION Patent covers the therapeutic use of a new composite formulation of anti-inflammatory compounds with unique advantages BioSenic’s new formulation lowers the dosage of arsenic trioxide by combining it with copper salts to maintain therapeutic efficacy, with the potential of administration through multiple routes, including intravenous, oral and other novel routes of administration Mont-Saint-Guibert, Belgium, April 18, 2023, 7.00am CET – BioSenic (Euronext Brussels and Paris: B
- Globe Newswire
BioSenic appoints Lieven Huysse, MD, as Chief Medical Officer
INSIDE INFORMATION Appointment to drive late-stage clinical development of BioSenic’s cell therapy and autoimmune disease platforms Mont-Saint-Guibert, Belgium, April 3, 2023, 7.30 am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces it has appointed Lieven Huysse, MD, as permanent Chief Medical Officer (CMO), effective 17 April 2023. Lieven Huysse will succeed Michel Wurm’s, MD, who was a
- Globe Newswire
BioSenic provides Financial Update and Financial Calendar 2023
INSIDE INFORMATION Mont-Saint-Guibert, Belgium, March 31, 2023, 7am CET - BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in severe autoimmune/inflammatory diseases and cellular repair, provides today a financial update and publishes its financial calendar for the year 2023. Financial Update As a result of cost management efforts made and payments received (mainly from Pregene) in Q1 2023, BioSenic Group now anticipates having sufficient cash to carry out it
- Globe Newswire
BioSenic publishes new data on the mechanism of action of arsenic trioxide (ATO)
INSIDE INFORMATION Combination of ATO with copper salts will allow BioSenic to work towards reducing the dosage of ATO in future trials overall and maintain efficacy Mont-Saint-Guibert, Belgium, March 30, 2023, 7am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in severe autoimmune/inflammatory diseases and cellular repair, today announces that data providing additional details about the mechanism of action of its lead API arsenic trioxide (ATO) to pr
- Globe Newswire
BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient population
REGULATED INFORMATION New analysis and formal identification of patient subsets open up further potential clinical development options for JTA-004 Mont-Saint-Guibert, Belgium, March 16, 2023, 7am CET - BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in severe autoimmune/inflammatory diseases and cellular repair, announces today it has re-evaluated the results of its Phase III trial of its enhanced viscosupplement JTA-004 targeting knee osteoarthritis (OA). B
- Globe Newswire
BioSenic optimizes statistical analysis for its ongoing ALLOB Phase IIb study for high-risk tibial fractures, requiring fewer patients and completes patient recruitment
Combination of advances in radiological assessments, new scientific insights in fracture healing and updated statistical analysis results in fewer patients needed for trial, and an earlier readout of relevant results, leading to significant reduction in trial time and costs Decisive statistical analysis results on primary endpoint now expected in Q2 2023 ALLOB subscription rights to become exercisable if the trial RUST score difference is higher than 1.26 in the statistical analysis at month thr
- Globe Newswire
BioSenic receives EUR 1 million from Pregene in accordance with terminated license agreement and expect new negotiations on common revisited grounds
Following the regaining of ALLOB global rights, BioSenic has received a final payment from Pregene linked to a previously achieved development milestone which has a significant impact on the financial fundamentals of BioSenic BioSenic continues to conduct preliminary discussions with Pregene, Link Health and other potential partners to move forward with the development and commercialization of ALLOB in other geographies, including the US Mont-Saint-Guibert, Belgium, February 21, 2023, 7am CET –
- Globe Newswire
BioSenic announces initiation of coverage by Portzamparc and Gilbert Dupont
Mont-Saint-Guibert, Belgium, February 14, 2023, 5:45 pm CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune / inflammatory diseases and cell repair, today announces that Portzamparc (BNP Paribas) and Gilbert Dupont (Groupe Société Générale) have both initiated coverage of its stock.Portzamparc (BNP Paribas) has published its financial note entitled “A future success inherited from the past”. Simultaneously, Gilbert Dupont (Groupe Soci
- Globe Newswire
BioSenic announces the approval and publication of the Prospectus for listing and admission to trading of the shares and subscription rights issued in the context of the capital increase by way of in kind contributions of Medsenic
REGULATED INFORMATION NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE TO OR WITHIN SWITZERLAND, THE UNITED STATES OF AMERICA, JAPAN, CANADA, AUSTRALIA, OR SOUTH AFRICA, OR ANY OTHER COUNTRY OR JURISDICTION WHERE ITS DISSEMINATION WOULD BE CONTRARY TO THE LAW OR OTHER RESTRICTIONS APPLY BioSenic announces the approval and publication of the Prospectus for listing and admission to trading of the shares and subscription rights issued in the context of the capital increase by way of in kind contributio
- Globe Newswire
BioSenic appoints Yves Sagot as Independent Director
REGULATED INFORMATION Mont-Saint-Guibert, Belgium, January 27, 2023, 7am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune / inflammatory diseases and cell repair, today announces the appointment of Yves Sagot as a Member of the Board and Independent Director. Yves Sagot has been appointed to the BioSenic Board for his experience and achievements for Relief Therapeutics SA and a number of specific aspects that mirror recent BioSenic
- Globe Newswire
BioSenic appoints Dr Carole Nicco as Chief Scientific Officer
Dr Nicco will oversee the development of pipeline across BioSenic’s cell therapy and autoimmune disease platform and will be responsible for R&D programs Mont-Saint-Guibert, Belgium, January 18, 2023, 7am CET – BioSenic(Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune /inflammatory diseases and cell repair, today announces it is strengthening its scientific team with the appointment of Dr. Carole Nicco, as Chief Scientific Officer (CSO). Dr Carole
- Globe Newswire
BioSenic appoints Michel Wurm, M.D. as Chief Medical Officer
REGULATED INFORMATION Appointment to further integrate BioSenic’s both cell therapy and autoimmune disease platforms under the responsibility of a new CMO and cross-pollinate the experiences of both teams to accelerate clinical progression Mont-Saint-Guibert, Belgium, December 02, 2022, 7am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the company specializing in serious autoimmune /inflammatory diseases and cell repair, today announces it has appointed Michel Wurm, MD, as interim Chief Me
- Globe Newswire
BioSenic SA: Transparency notifications received from François Rieger, Véronique Pomi, Capital Grand Est, FA DIESE 3 and CPH Banque
REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, November 21, 2022, 7am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in in the areas of innate immunity, inflammation and organ/function repair, today announces that it has received transparency notifications from François Rieger, Véronique Pomi, Capital Grand Est, FA DIESE 3 and CPH Banque. The notifications details c
- Globe Newswire
BioSenic SA provides update on its autoimmune disease platform based on ATO (arsenic trioxide)
REGULATED INFORMATION The autoimmune disease platform has completed a successful phase IIb trial targeting cGVHD (chronic Graft vs Host Disease), with a demonstrated efficacy of more than 75% Phase III is under preparation with expected accelerated examination by FDA Other indications should follow with wider market potential, including lupus and systemic sclerosis Mont-Saint-Guibert, Belgium, November 8, 2022, 7am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the company specialized in se
- Globe Newswire
BioSenic SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA
REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, November 4, 2022, 7am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in in the areas of innate immunity, inflammation and organ/function repair, today announces that it has received a transparency notification from S.R.I.W. SA (Société Régionale d’Investissement de Wallonie) dated 27 October 2022. The transparency notif
Globe NewswireBone Therapeutics to start a new Euronext equity story with a change of name to BioSenic, following the acquisition of a majority participation of Medsenic valued at EUR 40 million
REGULATED INFORMATION New company’s pipeline enriched with serious inflammatory indications in addition to its original cell therapy asset New Chairman, Board Members and Management appointed24,463,421 ALLOB subscription rights granted to all existing shareholders Mont-Saint-Guibert, Belgium, October 25, 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces the closing of
- Globe Newswire
Bone Therapeutics provides Third Quarter 2022 Business Update
REGULATED INFORMATION Mont-Saint-Guibert, Belgium, 21 October 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces its business update for the third quarter, ended 30 September 2022. “If approved by its shareholders, Bone Therapeutics’ acquisition of Medsenic majority participation will combine the allogeneic cell therapy product, ALLOB with Medsenic’s dedicated best-in-